Boussiotis VA - Search Results

1

CTLA-4 regulates induction of anergy in vivo.

Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. Greenwald RJ, et al. Among authors: boussiotis va. Immunity. 2001 Feb;14(2):145-55. doi: 10.1016/s1074-7613(01)00097-8. Immunity. 2001. PMID: 11239447 Free article.

2

Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation.

Boussiotis VA, Freeman GJ, Gribben JG, Daley J, Gray G, Nadler LM. Boussiotis VA, et al. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11059-63. doi: 10.1073/pnas.90.23.11059. Proc Natl Acad Sci U S A. 1993. PMID: 7504293 Free PMC article.

3

B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4.

Freeman GJ, Boussiotis VA, Anumanthan A, Bernstein GM, Ke XY, Rennert PD, Gray GS, Gribben JG, Nadler LM. Freeman GJ, et al. Among authors: boussiotis va. Immunity. 1995 May;2(5):523-32. doi: 10.1016/1074-7613(95)90032-2. Immunity. 1995. PMID: 7538442 Free article.

4

The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.

Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. Boussiotis VA, et al. Immunol Rev. 1996 Oct;153:5-26. doi: 10.1111/j.1600-065x.1996.tb00918.x. Immunol Rev. 1996. PMID: 9010717 Review. No abstract available.

5

Induction of T cell clonal anergy results in resistance, whereas CD28-mediated costimulation primes for susceptibility to Fas- and Bax-mediated programmed cell death.

Boussiotis VA, Lee BJ, Freeman GJ, Gribben JG, Nadler LM. Boussiotis VA, et al. J Immunol. 1997 Oct 1;159(7):3156-67. J Immunol. 1997. PMID: 9317113

6

Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells.

McAdam AJ, Chang TT, Lumelsky AE, Greenfield EA, Boussiotis VA, Duke-Cohan JS, Chernova T, Malenkovich N, Jabs C, Kuchroo VK, Ling V, Collins M, Sharpe AH, Freeman GJ. McAdam AJ, et al. Among authors: boussiotis va. J Immunol. 2000 Nov 1;165(9):5035-40. doi: 10.4049/jimmunol.165.9.5035. J Immunol. 2000. PMID: 11046032

7

PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ. Latchman Y, et al. Among authors: boussiotis va. Nat Immunol. 2001 Mar;2(3):261-8. doi: 10.1038/85330. Nat Immunol. 2001. PMID: 11224527

8

Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics.

Appleman LJ, Tzachanis D, Grader-Beck T, van Puijenbroek AA, Boussiotis VA. Appleman LJ, et al. Among authors: boussiotis va. J Mol Med (Berl). 2001;78(12):673-83. doi: 10.1007/s001090000180. J Mol Med (Berl). 2001. PMID: 11434720 Review.

9

CTLA-4 regulates cell cycle progression during a primary immune response.

Greenwald RJ, Oosterwegel MA, van der Woude D, Kubal A, Mandelbrot DA, Boussiotis VA, Sharpe AH. Greenwald RJ, et al. Among authors: boussiotis va. Eur J Immunol. 2002 Feb;32(2):366-73. doi: 10.1002/1521-4141(200202)32:2<366::AID-IMMU366>3.0.CO;2-5. Eur J Immunol. 2002. PMID: 11807776 Free article.

10

T cell anergy and costimulation.

Appleman LJ, Boussiotis VA. Appleman LJ, et al. Among authors: boussiotis va. Immunol Rev. 2003 Apr;192:161-80. doi: 10.1034/j.1600-065x.2003.00009.x. Immunol Rev. 2003. PMID: 12670403 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters